LOKOREGIONARNYE INTERVENTsIONNORADIOLOGIChESKIE TEKhNOLOGII V LEChENII GEPATOTsELLYuLYaRNOGO RAKA


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The article discusses the variants of locoregional treatment of hepatocellular carcinoma (HCC) in case of inability to perform liver transplantation or resection. These include the technologies of local destruction (percutaneous ethanol injection, radiofrequency ablation) and intravascular methods of antitumor therapy (transarterial chemoembolization, transarterial radioembolization). With an adequate selection of patients, these treatments are effective and safe. Currently, prospects for combined use of different locoregional interventional radiological techniques and their combination with systemic anticancer therapy in HCC are under investigation.

Толық мәтін

Рұқсат жабық

Әдебиет тізімі

  1. Kong W.T., Zhang W.W., Qiu Y.D., et al. Major complications after radiofrequency ablation for liver tumors: analysis of 255 patients. World J Gastroenterol 2009; 15: 2651-56.
  2. Livraghi T., Solbiati L., Meloni M.F., et al. Treatment of focal liver tumors with percutaneous radiofrequency ablation: complications encountered in a multicenter study. Radiology 2003; 226: 441-51.
  3. Lin S.M., Lin C.J., Lin C.C., et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 2004; 127: 1714-23.
  4. Giorgio A., Tarantino L., de Stefano G., Coppola C., Ferraioli G. Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors: 3-year experience with 336 patients at a single center. AJR 2005; 184: 207-11.
  5. Llovet J.M., Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48: 20-37.
  6. Orlando A., Leandro G., Olivo M., et al. Radiofrequency thermal ablation vs percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009; 104: 514-24.
  7. Bouza C., Lypez-Cuadrado T., Alcozar R., et al. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol 2009; 11(9): 31.
  8. Lencioni R.A., Allgaier H.P., Cioni D., et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation vs percutaneous ethanol injection. Radiology 2003; 228: 235-40.
  9. Shiina S., Teratani T., Obi S., et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122-30.
  10. Lin S.M., Lin C.J., Lin C.C., et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54: 1151-56.
  11. Brunello F., Veltri A., Crucci P. et al. Radio frequency ablation vs ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 2008; 43: 727-35.
  12. Brown D.B., Gould J.E., Gervais D.A., et al. Society of interventional radiology technology assessment committee and the international working group on image-guided tumor ablation transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc interv Radiol 2009; 20: 425-34.
  13. Lin D.Y., Liaw Y.F., Lee T.Y., et al. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma-a randomized controlled trial. Gastroenterology 1988; 94: 453-56.
  14. Pelletier G., Roche A., Ink O., et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-84.
  15. Group d'Etude et de Traitment du Carcinome Heґpatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256-61.
  16. Bruix J., Llovet J.M., Castells A., et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578-83.
  17. Pelletier G., Ducreux M., Gay F., et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 1998; 29: 129-34.
  18. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
  19. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
  20. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-39.
  21. Marelli L., Stigliano R., Triantos C., et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc intervent Radiol 2007; 30(1): 6-25.
  22. Llovet J.M., Di Bisceglie A.M., Bruix J., et al. Panel of experts in HCC-design clinical trials design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer inst 2008; 100: 698-711.
  23. Varela M., Real M.I., Burrel M., et al. Chemoembolisation of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-81.
  24. Poon R.T., Tso W.K., Pang R.W., et al. A phase I/II trial of chemoembolisation for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007; 5: 1100-18.
  25. Vogl T.J., Lammer J., Lencioni R., Malagari K., et al. Liver, Gastrointestinal, and Cardiac Toxicity in intermediate Hepatocellular Carcinoma Treated With PRECiSiON TACE With Drug-Eluting Beads: Results From the PRECISION V. Randomized Trial. AJR 2011; 197: 562-70.
  26. Sadick M., Haas S., Loehr M., et al. Application of DC beads in hepatocellular carcinoma: clinical and radiological results of a drug delivery device for transcatheter superselective arterial embolization. Onkologie 2010; 33: 31-37.
  27. Lammer J., Malagari K., Vogl T., et al. On behalf of the PRECISION V investigators prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECiSiON V study. Cardiovasc intervent Radiol 2010; 33: 41-52.
  28. Castells A., Bruix J., Ayuso C., et al. Transarterial embolization for hepatocellular carcinoma antibiotic prophylaxis and clinical meaning of postembolization fever. J Hepatol 1995; 22: 410-15.
  29. Vogl T.G., Lee C., Lencioni R., et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. J Clin Oncol 2010; 28: 14660A.
  30. Ibrahim S.M., Lewandowski R.J., Sato K.T., et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 2008; 14: 1664-69.
  31. Raoul J.L., Guyader D., Bretagne J.F., et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26: 1156-61.
  32. Vente M.A., Wondergem M., van der Tweel I., et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured metaanalysis. Eur Radiol 2009; 19: 951-59.
  33. Salem R., Lewandowski R.J., Mulcahy M.F., et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64.
  34. Kulik LM., Carr B.I., Mulcahy M.F., et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81.
  35. Sangro S., Carpanese L., Cianni R., et al. European multicenter evaluation of survival for patients with hepatocellular carcinoma (HCC) treated by radioembolization with 90y-labeled resin microspheres. J Clin Oncol 2010; 28: 4027A.
  36. Косырев В.Ю. Радиочастотная термоаблация в лечении злокачественных опухолей печени (показания, методология, результаты лечения). Автореферат дисс.. докт. мед. наук. Москва 2011.
  37. Виршке Э.Р., Трофимов И.А., Долгушин Б.И., Кукушкин А.В. Результаты артериальной химиоэмболизапции микросферами DC Bead с доксорубицином у больных с неоперабельным гепатоцеллюлярным раком / Сборник материалов V научно-практической конференции по интервенционной радиологии в онкологии. Москва, 2012. С. 87-8.
  38. Kagawa T., Koizumi J., Kojima S. et al. Transcatheter Arterial Chemoembolization Plus Radio frequency Ablation Therapy for Early Stage Hepatocellular Carcinoma. Cancer 2010; 116: 3638-44.
  39. Yamakado K., Nakatsuka A., Takaki H., et al. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology 2008; 247: 260-66.
  40. Schoenleber S.J., Kurtz D.M., Talwalkar J.A., et al. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009; 100: 1385-92.
  41. Wang B., Xu H., Gao Z.Q., et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008; 49: 523-29.
  42. Song B.C., Chung Y.H., Kim J.A., et al. Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: a prospective study. Cancer 2001; 91: 2386-93.
  43. Strebel B.M., Dufour J.F. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 2008; 8: 1743-49.
  44. Chung Y., Kim B., Chen C., et al. Study in Asia of the combination of transcatheter arterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial (START): second interim safety and efficacy analysis [abstract]. J Clin Oncol 2010; 28: abstract 4026.
  45. ClinicalTrials.gov. Chemoembolization with or without sorafenib tosylate in treating patients with liver cancer that cannot be removed by surgery. Updated November 11, 2010. Available at: http://www.clinicaltrials.gov/ct2/show/NCT010049 78?term=sora fenib+ecog+1208&rank=1.
  46. UK Clinical Research Network: Portfolio Database. TACE-2 - a randomized placebo-controlled, double blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC). Available at: http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=5347.
  47. Hoffmann K., Glimm H., Radeleff B., et al. Prospective, randomized, double-blind, multicenter, phase III clinical study on transarterial chemoembolization (TACE) combined with sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer 2008; 8: 349.
  48. Dhanasekaran R., Kooby D.A., Staley C.A., et al. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug-eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC) [published online ahead of print March 8, 2010]. J Surg Oncol. doi: 10.1002/jso.21522.
  49. Malagari K., Pomoni M., Kelekis A., et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with Beadblock for hepatocellular carcinoma [published online ahead of print November 24, 2009]. Cardiovasc Intervent Radiol. doi: 10.1007/s00270-009-9750-0.
  50. Song M.J., Chun H.J., Song D.S. et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012 Jul 20. pii: S0168-8278(12)00583-1. doi: 10.1016/j.jhep.2012.07.017.
  51. Louis C., Dewas S., Mirabel X. et al. Stereotactic Radiotherapy of Hepatocellular Carcinoma: Preliminary Results. Technol Cancer Res Treat 2010; 5: 479-87.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2012

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>